Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 119

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 2
Chunk 119
---
 in our deferred grant funding liability, $2.3 million in accounts payable, $1.2 million in accrued expenses, and $0.4 million operating lease liability, offset by increases of $2.9 million in prepaid expenses, $0.4 million in other receivables, and $0.4 million in interest payable.

Net cash used in investing activities

Net cash used in investing activities for the nine months ended September 30, 2025 and 2024 related to purchases of property and equipment. 

43

Net cash provided by financing activities 

Net cash provided by financing activities for the nine months ended September 30, 2025 resulted primarily from (i) approximately $17.6 million in net proceeds from sales of our common stock under our ATM sales agreement, (ii) approximately $2.0 million of net proceeds from sales of our common stock under our purchase agreement with Lincoln Park, and (iii) approximately $0.5 million in proceeds from the financing of certain director and officer and other liability insurance premiums, partially offset by (A) approximately $0.9 million in payments on our facility financing lease and (B) approximately $0.4 million in payments on the insurance premium financing note payable.

Net cash provided by financing activities for the nine months ended September 30, 2024 resulted primarily from (i) approximately $0.6 million in proceeds from the financing of certain director and officer and other liability insurance premiums and (ii) approximately $0.4 million in net proceeds from the sales of our common stock under our ATM sales agreement, partially offset by approximately $0.4 million in payments on the insurance premium financing note payable.

Contractual Obligations and Other Commitments

License and Royalty Agreements

We have assembled our pipeline primarily through acquisitions, in-license agreements, and other collaborations. We agreed to make royalty and milestone payments, and in some cases annual license fee payments, under the license and development agreements under which we acquired rights to intellectual property from third parties. For information about these obligations see Note 3 "Strategic Agreements—Strategic Agreements for Pipeline Development" to the accompanying condensed consolidated financial statements. The amount and timing of most of these payments are difficult to predict because the timing of milestone payments for pre-commercial programs generally depends on the progress of and success in development of a particular program, which is subject to many risks and uncertainties as discussed elsewhere in this report and difficult to predict, and the timing and amount of royalty and milestone payments related